Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 7 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Camba-Pharma from Gent, company number BE0717740414, closed financial year 2025 with a result of € 47,651 after tax. For that financial year Camba-Pharma recorded a gross margin of € 69,398 and equity of € 137,100. Compared with financial year 2024, the result moved from € 36,955 to € 47,651. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on April 8, 2026.
€ 137,100
▲ 31% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 47,651
▲ 29% vs 2024
Profit after tax over the fiscal year.
€ 6,440
▲ 17% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 15,000 paid out
31 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 1,108
▼ 25% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 259,591
▼ 13% vs 2024
€ 42,037 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 8,850
▲ € 8,529 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 11,626
▲ 51% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 50,436 | € 49,374 | € 57,060 | € 69,398 | ▲ 22% |
| Profit after taxes | € 31,841 | € 32,054 | € 36,955 | € 47,651 | ▲ 29% |
| Equity | € 50,441 | € 67,494 | € 104,449 | € 137,100 | ▲ 31% |
| Total debts | € 408,449 | € 390,145 | € 351,903 | € 300,724 | ▼ 15% |
| Cash | € 3,901 | € 14,216 | € 5,527 | € 6,440 | ▲ 17% |
| Retained profit | € 31,841 | € 48,894 | € 85,849 | € 118,500 | ▲ 38% |
| Dividend | € 41,233 | € 15,000 | € 0 | € 15,000 | |
| Bank debt | € 373,911 | € 333,470 | € 296,865 | € 259,591 | ▼ 13% |
| Balance sheet total | € 458,890 | € 457,640 | € 456,352 | € 437,825 | ▼ 4% |
Key figures of Camba-Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Camba-Pharma?
What happened at Camba-Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 47,651 (▲ 29% vs 2024). Source: NBB ↗
- New establishment in Gent. KBO
- Camille Baetslé became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 31,841 profit in 2022 to € 47,651 profit in 2025.
Paid € 55,831 in corporate taxes since 2022.
Best year ever: 2025, with € 47,651 profit.
Paid out € 71,233 in dividends to the owners in total.
Management
Behind Camba-Pharma is Camille Baetslé. It owns 50% of Bioclin itself.
Directors
According to the 2025 annual accounts
since 2019
Establishments
Establishment units
Physical locations of this company
Droogveldeweg 7
9031 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0717.740.414
- VAT number
- BE 0717.740.414
- Registered office
- Droogveldeweg 7, 9031 Gent
- Names & denominations
- Camba-Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 January 2019
- Peppol
- Active · Active since 24 Nov 2023
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van holdings
Holdings